Literature DB >> 9142908

Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome.

M B Fallon1, G A Abrams, J W McGrath, Z Hou, B Luo.   

Abstract

Hepatopulmonary syndrome (HPS) causes impaired oxygenation due to intrapulmonary vasodilatation in patients with cirrhosis. Chronic common bile duct ligation (CBDL) in the rat results in gas-exchange abnormalities similar to HPS, but intrapulmonary vasodilatation has not been evaluated. We assess intrapulmonary vasodilatation, measured in vivo, after CBDL. Sham, 2- and 5-wk CBDL, and 3-wk partial portal vein ligated (PVL) rats had hepatic and lung injury, portal pressure, and arterial blood gases assessed. The pulmonary microcirculation was evaluated by injecting microspheres (size range 5.5-10 microm) intravenously and measuring the size and number of microspheres bypassing the lungs in arterial blood. CBDL animals developed progressive hepatic injury and portal hypertension accompanied by gas-exchange abnormalities and intrapulmonary vasodilatation. PVL animals, with a similar degree of portal hypertension, did not develop intrapulmonary vasodilatation or abnormal gas exchange. No lung injury was observed. CBDL, but not PVL, causes progressive intrapulmonary vasodilatation, which accompanies worsening arterial gas exchange. These findings validate CBDL as a model to study HPS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142908     DOI: 10.1152/ajpgi.1997.272.4.G779

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  45 in total

Review 1.  Hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams
Journal:  Curr Gastroenterol Rep       Date:  2000-02

2.  Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans.

Authors:  David G Koch; Galina Bogatkevich; Venkat Ramshesh; John J Lemasters; Renan Uflacker; Adrian Reuben
Journal:  Dig Dis Sci       Date:  2011-10-01       Impact factor: 3.199

Review 3.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

4.  Pentoxifylline attenuation of experimental hepatopulmonary syndrome.

Authors:  Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; Balu K Chacko; Rakesh P Patel; Michael B Fallon
Journal:  J Appl Physiol (1985)       Date:  2006-11-16

Review 5.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

6.  Effects of caffeic acid phenethyl ester (CAPE) on hepatopulmonary syndrome.

Authors:  Ahmet Tekin; Serdar Türkyılmaz; Tevfik Küçükkartallar; Murat Cakır; Hüseyin Yılmaz; Hasan Esen; Burhan Ateş; Ilhan Ciftci; Adil Kartal
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

7.  The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.

Authors:  Wenli Yang; Junlan Zhang; Bingqian Hu; Wei Wu; Julie Venter; Gianfranco Alpini; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

8.  Effects of dexamethasone on small bowel and kidney oxidative stress and histological alterations in bile duct-ligated rats.

Authors:  Hayrettin Ozturk; Halil Eken; Hulya Ozturk; Huseyin Buyukbayram
Journal:  Pediatr Surg Int       Date:  2006-08-01       Impact factor: 1.827

Review 9.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

10.  Constitutively active endothelial Notch4 causes lung arteriovenous shunts in mice.

Authors:  Doug Miniati; Eric B Jelin; Jennifer Ng; Jianfeng Wu; Timothy R Carlson; Xiaoqing Wu; Mark R Looney; Rong A Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-11-20       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.